Christopher Benecchi
Corporate Officer/Principal en SAGE THERAPEUTICS, INC. .
Fortuna: 364 118 $ al 31/03/2024
Perfil
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019.
Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0.03% | 13/02/2024 | 19 430 ( 0.03% ) | 364 118 $ | 31/03/2024 |
Cargos activos de Christopher Benecchi
| Empresas | Cargo | Inicio |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Corporate Officer/Principal | 21/09/2021 |
Antiguos cargos conocidos de Christopher Benecchi.
| Empresas | Cargo | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2021 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01/08/2019 |
Formación de Christopher Benecchi.
| Duke University | Masters Business Admin |
| Colby College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SAGE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
- Bolsa de valores
- Insiders
- Christopher Benecchi
